Relations of insulin sensitivity to longitudinal blood pressure tracking: variations with baseline age, body mass index, and blood pressure
Beyond modest lipid improvements, GLP-1 receptor agonists have demonstrated substantial cardiovascular benefits in large-scale outcome trials, establishing them as important cardioprotective agents for appropriate patients
Simon Barquera, president of the World Obesity Federation, told AFP that the medication alone will not reverse the global rise in obesity. Obesity is a complex, chronic disease, he said, noting the importance of prevention efforts and healthier habits
Leptin and CCK selectively activate vagal afferent neurons innervating the stomach and duodenum
The first available amylin agonist was pramlintide, which is already approved for treatment of type 1 and type 2 diabetes in conjunction with insulin [4]